GNTA
Genenta Science S.p.A.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Genenta Science S.p.A.
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
No changes.
No changes.
No peers for Genenta Science S.p.A. yet.
No peers for Genenta Science S.p.A. yet.
Annual filing, covered
20-F parsed · Apr 1 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
20-F parsed · Apr 1 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon and other immune-gene therapy programs for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon and other immune-gene therapy programs for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
Genenta Science S.p.A.
0.62
Expected move
No implied move.
| Manager | Value | % base | |
|---|---|---|---|
| Eurizon Capital SGR S.p.A. | $662,400 | 49.95% | 0.00% |
| Allianz | $430,652 | 32.47% | 0.00% |
| SmartHarvest Portfolios | $80,695 | 6.09% | −67.38% |
| Virtu Financial | $68,000 | 5.13% | new |
| Simplicity Wealth | $34,206 | 2.58% | +52.24% |
| Manager | Value | % base | |
|---|---|---|---|
| Eurizon Capital SGR S.p.A. | $662,400 | 49.95% | 0.00% |
| Allianz | $430,652 | 32.47% | 0.00% |
| SmartHarvest Portfolios | $80,695 | 6.09% | −67.38% |
| Virtu Financial | $68,000 | 5.13% | new |
| Simplicity Wealth | $34,206 | 2.58% | +52.24% |
−11.70%
shares held · 7 largest managers